$INCY

Tray Thomas sold $264K of INCY

Tray Thomas (Principal Accounting Officer) sold 2,639 shares of INCYTE CORP (INCY) at $100.00 ($0.26M total) on 2026-06-04 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tray Thomas
Published Jun 8, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 8, 2026, 8:07 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$INCY
Neutral
high confidence
Mentioned
$INCY
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INCYNeutralLow
01

Why it matters

The newest fact is the disclosed sale size, execution date (June 4), and that it was conducted under a pre-arranged Rule 10b5-1 plan.

02

Market read

This is a routine insider sale disclosure with limited incremental trading signal for INCY.

03

What to watch

The article provides only the sale details (size/price/plan) and no context on total compensation, tax-motivated selling, or whether other insiders are selling/buying concurrently.

Relevance 3/10Novelty 2/10Timing: Filed June 8; sale executed June 4.

Background

The article reports an SEC Form 4 insider transaction for Incyte, filed via EDGAR.

Company-level read

Ticker impact

$INCYNeutralHigh confidence
Context

Incyte Form 4 shows Tray Thomas (principal accounting officer) sold 2,639 shares at $100/share under a 10b5-1 plan.

Expected impact

Low likelihood of sustained price impact; any effect is likely short-lived and sentiment-driven.

Evidence & confidence

The filing is a Form 4 insider sale with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight.

Market effects

No sector read-through; this is company-specific insider transaction data only.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution; traders may still monitor for clustering of sales.

Key entities

  • INCY

    Incyte Corp; subject of the Form 4 insider sale disclosure.

  • Tray Thomas

    Principal Accounting Officer who sold shares.

  • Rule 10b5-1 plan

    Pre-arranged plan indicating the sale was scheduled in advance.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MIRMHighAI 9/10

Mirum wins FDA Atebrioz approval for FOP patients 12+

Mirum Pharmaceuticals (MIRM) received FDA approval for Atebrioz to treat FOP in patients aged 12+. The drug, developed by Incyte (INCY), showed a reduction in new bone-lesion volume in a 63-patient study. U.S. availability is expected in October, with a patient support program in place. Mirum shares closed at $89.70, Incyte at $123.89 on Friday.

$MIRMHighAI 9/10

Mirum Pharmaceuticals, Inc. and Incyte: Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Mirum Pharmaceuticals (MIRM) and Incyte (INCY) announced FDA approval of Atebrioz (zilurgisertib) for treating fibrodysplasia ossificans progressiva (FOP) in patients aged 12+. The once-daily oral ALK2 inhibitor showed efficacy in reducing heterotopic ossification in clinical trials. Atebrioz is expected to be available in the U.S. in October, with eligible patients paying as little as $0 per month through Mirum's patient support program.

$INCYHighAI 8/10

EMA OKs Two Options for Refractory Inflammatory Conditions

The EMA's CHMP approved Povofortay (Incyte) for marketing to treat moderate to severe hidradenitis suppurativa (HS) in adults who failed anti-TNF therapy. It is the first oral option for HS, reducing pain and lesions. Cosentyx (Novartis) gained a new indication for polymyalgia rheumatica (PMR) in adults unresponsive to glucocorticoids. Both drugs showed efficacy in clinical trials.